Experimental and Molecular Therapeutics

Abstract 1238: Treating estrogen receptor (ER)-negative and triple-negative breast cancer by targeting STAT3 signaling with putative STAT3 inhibitors

Pub Date : 2021-07-01 DOI: 10.1158/1538-7445.AM2021-1238 Hyejin Kim, Doerte R. Fricke, Jimin Xu, Haiying Chen, Jia Zhou, Q. Shen

Abstract 1130: First-in-class KAT6A/KAT6B inhibitor CTx-648 (PF-9363) demonstrates potent anti-tumor activity in ER+ breast cancer with KAT6A dysregulation

Pub Date : 2021-07-01 DOI: 10.1158/1538-7445.AM2021-1130 Shikhar Sharma, Jay Chung, S. Uryu, Amanda M. Rickard, N. Nady, Showkhin Khan, Zhenxiong Wang, Yong Zhang, Haikuo Zhang, P. Kung, E. Greenwald, K. Maegley, P. Bingham, Hieu Lam, Y. E. Bozikis, Hendrik Falk, E. Allan, V. Avery, M. Butler, M. Camerino, Catalina Carrasco-Pozo, S. Charman, Melissa J. Davis, M. Dawson, Dawson Sarah-Jane, M. de Silva, M. Dennis, O. Dolezal, Rachel Lagiakos, G. Lindeman, Laura MacPherson, S. Nuttall, T. Peat, B. Ren, Alexandra E Stupple, Elliot E. Surgenor, Chin Wee Tan, T. Thomas, J. Visvader, A. Voss, F. Vaillant, K. White, J. Whittle, Yuqing Yang, Soroor Hediyeh-zadeh, P. Stupple, I. Street, B. Monahan, T. Paul

Abstract 1427: Sensitizing HL60 acute myeloid leukemia cells to decitabine with pterostilbene

Pub Date : 2021-07-01 DOI: 10.1158/1538-7445.AM2021-1427 Cayla Boycott, B. Stefańska